Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors

被引:0
作者
Minas P. Economides
Srdan Verstovsek
Naveen Pemmaraju
机构
[1] The University of Texas School of Health Sciences at Houston,Department of Internal Medicine
[2] The University of Texas MD Anderson Cancer Center,Department of Leukemia
来源
Current Hematologic Malignancy Reports | 2019年 / 14卷
关键词
Ruxolitinib; Myeloproliferative neoplasms; Novel therapies; JAK inhibitors; Novel drugs;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:460 / 468
页数:8
相关论文
共 1003 条
[41]  
Moore S(2013)Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276 Leukemia 27 2357-581
[42]  
Galinsky I(2014)Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy Cancer Discov 4 527-1637
[43]  
DeAngelo DJ(2009)Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia Br J Haematol 145 624-76
[44]  
Clark JJ(2007)Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis Leuk Res 31 1503-410
[45]  
Lee SJ(2000)Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor Protein Eng 13 575-26734
[46]  
Golub TR(2019)Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm N Engl J Med 380 1628-5033
[47]  
Wadleigh M(2018)Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis Blood 132 1773-331
[48]  
Gilliland DG(2012)Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18 64-2452
[49]  
Levine RL(2003)A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Nature 425 407-e188
[50]  
Nangalia J(2005)Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J Biol Chem 280 26729-232